Entera Bio opened lower at $3.20, compared with its previous close of $3.22. In the last trading session, the stock traded between $3.13 and $3.24. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Entera Bio is now worth
$ 84.62
Resulting in a loss of
$ 15.38 (15.38%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
+$0.00 (+0.12%)
Day High
$3.24
Day Low
$3.13
Day Open
$3.20
Prev Close
$3.22
Volume
1,12,419
1W Return
3.17%
1M Return
21.25%
3M Return
7.97%
6M Return
175.56%
1Y Return
7.11%
Market Cap ($ Mn)
561
PE Ratio
-
PB Ratio
20.59
PEG Ratio
-
ROE
-78.30%
ROCE
-76.21%
EPS (TTM)
$-0.15
1 Week
3.17%
1 Month
21.25%
3 Months
7.97%
6 Months
175.56%
9 Months
96.59%
Entera Bio Q3FY26 Results: Net loss widens to $15.6M, cash at $265.9M
Net loss widened to $15.6 million in Q3FY26 from $3.2 million YoY. Loss per share of $(0.11) missed analyst estimate of $(0.07) by 57.14%. Non-cash warrant remeasurement of $7.5 million drove majority of loss increase. Cash position stands at $265.9 million, funding operations into 2030.
6 days agoEntera Bio CEO to address investors at three fall healthcare conferences
Entera Bio CEO Miranda Toledano will speak at three fall investor conferences. Key dates include September 10 in New York and November events in Boston and Miami. The company highlighted progress on EB613, which met Phase 2 endpoints in 161 patients. Entera continues developing oral peptide therapies for osteoporosis and metabolic conditions.
2mo agoEntera Bio Q2 EPS misses estimate as net loss widens to $7.3 million
Entera Bio reported a Q2 net loss of $7.3 million, missing EPS estimates due to warrant remeasurement costs. The company secured a $275 million private placement to fund clinical trials for its osteoporosis candidate EB613 through 2030.
3mo agoEntera Bio Phase 2 EB613 data selected for ASBMR 2026 Plenary session
Entera Bio announced that post-hoc Phase 2 data for EB613, an oral anabolic therapy for osteoporosis, has been selected for two presentations at the ASBMR 2026 Annual Meeting in Boston. The data demonstrates enhanced efficacy in high-risk patients, bolstering the case for its upcoming Phase 3 trial.
3mo agoEntera Bio CEO Miranda Toledano to speak at Canaccord Genuity conference
Entera Bio Ltd. confirmed that CEO Miranda Toledano will join a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The session will be webcast live and replayed for 365 days. Entera continues to advance its oral peptide pipeline, including EB613 for osteoporosis, which recently met Phase 2 endpoints.
3mo agoEntera Bio raises $275M in oversubscribed placement, shares rebound on funding news
Entera Bio Ltd. secured $275 million in an oversubscribed private placement to fund Phase 3 trials for its osteoporosis candidate EB613. The deal, led by BVF Partners, extends the cash runway into 2030 and includes board designation rights for BVF. Shares rebounded on the news despite dilution concerns.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Entera Bio is now worth
$ 84.62
Resulting in a loss of
$ 15.38 (15.38%)
Note: Past profits do not guarantee future returns.
